Non-viral gene delivery

Privately held biotechnology company enGene
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00
VANCOUVER—Privately held biotechnology company enGene announced it has acquired a license to a non-viral gene integration technology from Burlingame, Calif.-based Poetic Genetics. The technology will support enGene's proprietary GEMS (Gut Endocrine-cell Modification System) gene delivery platform.
 
Under the terms of the agreement, enGene gains exclusive worldwide rights to Poetic's technology, which allows therapeutic genes to be integrated into intestinal cells in vivo, facilitating sustained production of drugs within the body. In exchange, Poetic will receive milestone payments in the form of equity in the Canadian company, cash payments and royalties from commercial sales.
 
 enGene also announced the initiation of a US$15 million Series A financing round to support the preclinical and clinical development of its GEMS-Insulin. "The timing is right for us to attract institutional investors given the breadth of our platform technology, the importance of the change to non-viral delivery, and the reasonable timeframe for achieving preliminary human efficacy data in the GEMS-Insulin program," said Eric Adams, enGene president and CEO.

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Tackling mycoplasma contamination in biotherapeutic production
DNA-based testing is emerging as a sensitive way to uncover and control a hidden threat in biomanufacturing.
Surface rendering of two interacting proteins (green and peach) bound together by a small molecule ligand at their interface, illustrating a protein-ligand binding event.
Learn how molecular dynamics, AI-aided design, and structural insights combine to reshape how therapeutic proteins are created, validated, and optimized.
Stem cells are shown as clear, purple, and blue spheres against a dark blue and black background.
Human-relevant, ready-to-use stem cell models are reshaping drug discovery, toxicity testing, and personalized medicine.
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue